The development funding bond is a royalty deal that was never a royalty: fixed multiple, fixed schedule, guaranteed by the parent, paid regardless of sales. Why both sides chose debt over a true sale, the tax and accounting logic, and why the structure stays a category of two.

A decade in, no token has paid a pharmaceutical royalty. When decentralized science finally produced a commercial deal, the money went to equity holders, which is exactly where securities law sends it. Every eighteen months someone announces that pharmaceutical royalties are about to go on-chain. The pitch is stable:

The week in numbers July 4 to July 11, 2026: four acquisitions, six royalty-bearing originations, one synthetic royalty (Oberland / MeiraGTx), one €3.0B structured-equity monetisation (Apollo / Bayer), one structured-credit refinancing (OrbiMed / TOI), one milestone cash event (Aligos), and two negative royalty re-rates (Ionis WAINUA, GSK / Alector)

Since the September 2025 analysis, the disease-linked bond category has separated into families that no longer behave alike. Instruments that place principal at risk on a parametric trigger or a measured outcome saw little or no new issuance in 2024 to 2026. Instruments that rest on a sovereign credit,

Venture philanthropy: the RD Fund is donor-backed and evergreen, with $59.5M net assets, 18 companies and $0 royalty income on file. Its value is upstream, originating the rare-disease assets whose royalties later land on other desks.

Pacira BioSciences owns its non-opioid drugs rather than licensing a platform, so its royalty life runs backwards: it litigated one royalty out of existence, wrote a negative royalty against EXPAREL's own volumes to 2039, and in June 2026 sold iovera° to Zimmer Biomet for up to $140 million.

A pre-funded warrant is a paid-up share that counts for EPS, disappears from beneficial ownership, and reappears as owned stock for tax. How the gap between the three lets a fund hold 15 percent while reporting 9.99, and where it meets royalty finance.

A minimum guarantee is a written put. Where it sits on the sale-to-loan boundary sets the accounting, tax and bankruptcy outcome of a healthcare royalty deal.

A drug that misses its billion-dollar consensus still writes real cash every quarter. Royalty capital never priced the story, only the floor left behind. When that floor is a cheap, de-risked asset, when it is a value trap, and what a decade of deals and the forecast data actually show.